This Week in Cardiology Podcast Por Medscape arte de portada

This Week in Cardiology

This Week in Cardiology

De: Medscape
Escúchala gratis

This podcast delivers Dr. John Mandrola's summary and perspective on top news of the week that cardiologists can't miss. This podcast is intended for US health professionals only.Copyright 2019, Medscape Ciencia Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Feb 20 2026 This Week in Cardiology

    Feb 20 2026 This Week in Cardiology
    Feb 20 2026

    EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR

    • 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063
    • EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
    • EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
    • EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813
    • Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034
    • TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092
    • TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031
    • UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251
    • Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA

    II DNR in the Hospital

    • Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203
    • GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/

    III Yet another failure of Targeted Hypothermia

    • 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193
    • TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591

    IV Good news in HFpEF Evidence

    • ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016

    V GLP-1 as AF drugs

    • Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    25 m
  • Feb 13 2026 This Week in Cardiology

    Feb 13 2026 This Week in Cardiology
    Feb 13 2026

    Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I TUXEDO-2 Trial

    • TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869
    • ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973

    II VERITAS Study of Dual-Seal LAAO

    • VERITAS Study https://doi.org/10.1016/j.jacep.2026.01.021

    III PFA vs RF over 4 years

    • Advent-LTO study https://www.nature.com/articles/s41591-026-04246-4
    • ADVENT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
    • SPHERE PER-AF Study https://www.nature.com/articles/s41591-024-03022-6
      SINGLE SHOT CHAMPION Study https://www.nejm.org/doi/full/10.1056/NEJMoa2502280
    • BEAT PAROX-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829

    IV What's in a Name — Use of the Term "Provider"

    • Physicians Are Not Providers: The Ethical Significance of Names https://www.acpjournals.org/doi/10.7326/ANNALS-25-03852

    V Coffee and Dementia Risk

    • Coffee/Tea Intake and Dementia Risk https://jamanetwork.com/journals/jama/fullarticle/2844764
    • Mandrola Commentary: Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709

    VI Lifestyle interventions Post AF ablation

    • Improving Outcomes of AF by Lifestyle Interventions https://academic.oup.com/eurheartj/article/47/6/669/8243674

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    30 m
  • Feb 06 2026 This Week in Cardiology

    Feb 06 2026 This Week in Cardiology
    Feb 6 2026

    Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I PREVENT Score

    • PREVENT Equations in Young Adults https://doi.org/10.1016/j.jacc.2025.12.019
    • Hospital Readmission Reduction Program for HF

    https://pmc.ncbi.nlm.nih.gov/articles/PMC7664458/

    II A New Breakthrough in LDL-C Management With an Oral PCSK9 Inhibitor

    https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8

    • CORALreef Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002
    • CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756

    III A Win for the Factor XI Inhibitor Asundexian – OCEANIC Stroke Trial

    https://www.medscape.com/viewarticle/first-clear-win-factor-xia-inhibitors-stroke-reduced-2026a10003t0

    • OCEANIC-STROKE Slide deck https://clinicaltrialresults.org/wp-content/uploads/2026/02/26-02-02_ISC_OCEANIC-STROKE-primary.pdf
    • OCEANIC-AF Study Stopped Early https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/

    IV Statin Side Effects

    • Assessment of AEs Attributed to Statins -- Meta-analysis https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext
    • N-of-1 Trial to Assess AEs of Statins https://www.nejm.org/doi/full/10.1056/NEJMc2031173
    • When to Start a Statin Is a Decision About Preference -- Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808

    V Heart Disease Statistics

    • CV Statistics in the US, 2026 https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    24 m
Todas las estrellas
Más relevante
Dr Mandrola delivers excellent updates on recent publications. The podcast is just the thing for a commute: not too superficial, not too detailed, and do a great job placing the new clinical advances in the context of contemporary practice.

recommend to colleagues

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
As a former Cardiology PA now working on the academic side of medicine, I’ve been out of practice for several years. Preparing to teach a cardiology course at a new program, I started brushing up on material—and stumbled across Dr. Mandrola’s podcast. Wow. I wish I had known about this resource back when I was still practicing clinically.

In just a short time, I’ve learned what’s new since I left practice, and even picked up on things I probably should have known better back then. More importantly, I’ve gained an entirely new appreciation for how to critically review clinical trials and recognize bias.

What sets this podcast apart is Dr. Mandrola’s humility and honesty: his willingness to point out flaws in studies, to admit when he doesn’t know something, and to change his perspective when the evidence supports it. That kind of intellectual honesty builds trust, and it makes him feel less like a distant expert and more like a fellow learner walking through the field with you.

I’ve flown through the last two years of episodes in just a week, and I’m looking forward to being a dedicated listener moving forward. Thank you, Dr. Mandrola, for approaching cardiology not as a lecture, but as a thoughtful, ongoing conversation.

Honest, Insightful, and Incredibly Valuable

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
I absolutely love listening to this podcast and feel I practice medicine very similarly. I love your critical review of studies as it brings these areas to light. I especially loved your comment at the end of this podcast discussing the reasoning to go into EP. I agree with your reasons, and consider them the same for most fields of medicine, especially any in cardiology, which I practice as a PA in and have for 14 years. Going into medicine just for the money should never be the reason as it will only lead to frustration and burnout. Thank you for your honest reviews and feedback each week.

EP is not about the money -love this statement

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
Me gusta el escepticismo del Dr Mandrola. Habla de su objetividad y su compromiso con la ciencia bien hecha

Muy informativo

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.